Trial · NCT03379675
Adverse events24
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 24
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhoea | Gastrointestinal disorders | Treatment A: JNJ-53718678 500 mg | 5 | 24 | 5 |
| other | Diarrhoea | Gastrointestinal disorders | Treatment B: JNJ-53718678 80 mg + Placebo | 9 | 24 | 14 |
| other | Diarrhoea | Gastrointestinal disorders | Treatment C: Placebo | 9 | 24 | 10 |
| other | Vomiting | Gastrointestinal disorders | Treatment A: JNJ-53718678 500 mg | 0 | 24 | 0 |
| other | Vomiting | Gastrointestinal disorders | Treatment B: JNJ-53718678 80 mg + Placebo | 3 | 24 | 3 |
| other | Vomiting | Gastrointestinal disorders | Treatment C: Placebo | 1 | 24 | 1 |
| other | Urinary Tract Infection | Infections and infestations | Treatment A: JNJ-53718678 500 mg | 1 | 24 | 1 |
| other | Urinary Tract Infection | Infections and infestations | Treatment B: JNJ-53718678 80 mg + Placebo | 2 | 24 | 2 |
| other | Urinary Tract Infection | Infections and infestations | Treatment C: Placebo | 0 | 24 | 0 |
| other | Dizziness | Nervous system disorders | Treatment A: JNJ-53718678 500 mg | 0 | 24 | 0 |
| other | Dizziness | Nervous system disorders | Treatment B: JNJ-53718678 80 mg + Placebo | 2 | 24 | 2 |
| other | Dizziness | Nervous system disorders | Treatment C: Placebo | 0 | 24 | 0 |
| other | Headache | Nervous system disorders | Treatment A: JNJ-53718678 500 mg | 0 | 24 | 0 |
| other | Headache | Nervous system disorders | Treatment B: JNJ-53718678 80 mg + Placebo | 2 | 24 | 2 |
| other | Headache | Nervous system disorders | Treatment C: Placebo | 3 | 24 | 3 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Treatment A: JNJ-53718678 500 mg | 0 | 24 | 0 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Treatment B: JNJ-53718678 80 mg + Placebo | 0 | 24 | 0 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Treatment C: Placebo | 3 | 24 | 3 |
| other | Pruritus | Skin and subcutaneous tissue disorders | Treatment A: JNJ-53718678 500 mg | 0 | 24 | 0 |
| other | Pruritus | Skin and subcutaneous tissue disorders | Treatment B: JNJ-53718678 80 mg + Placebo | 1 | 24 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03379675/events